Vestal Point Capital Fully Exits Position in Day One Biopharmaceuticals, Inc. (DAWN)

Vestal Point Capital, LP and its Managing Partner, Ryan Wilder, have filed an amendment to their Schedule 13G regarding Day One Biopharmaceuticals, Inc. (DAWN). The filing, dated May 15, 2026, reflects an event date of March 31, 2026, and indicates that the reporting persons have completely exited their position in the company. As of the filing date, both Vestal Point Capital, LP and Mr. Wilder report zero shares of common stock owned, representing a 0% ownership stake. This is a significant decrease from any previous holdings, as the reporting persons now own less than 5% of the class of securities. The securities were originally held in the ordinary course of business by Vestal Point Capital, LP acting as an investment adviser to a managed fund and account. The filing confirms that the reporting persons no longer have any voting or dispositive power over the issuer's common stock, effectively terminating their status as significant shareholders.